# Phase II Study of Becotatug Vedotin Plus Pucotenlimab for Advanced Refractory Solid Tumors With EGFR-Positive

> **NCT07712029** · PHASE2 · RECRUITING · sponsor: **Tianjin Medical University Second Hospital** · enrollment: 32 (estimated)

## Conditions studied

- Advanced Refractory Solid Tumors
- EGFR Gene Overexpression

## Interventions

- **DRUG:** Becotatug Vedotin
- **DRUG:** Pucotenlimab

## Key facts

- **NCT ID:** NCT07712029
- **Lead sponsor:** Tianjin Medical University Second Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-01
- **Primary completion:** 2028-08-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-07-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07712029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07712029, "Phase II Study of Becotatug Vedotin Plus Pucotenlimab for Advanced Refractory Solid Tumors With EGFR-Positive". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07712029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*